Not by DNA alone: How the epigenetics revolution is fostering new medicines

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

The article, by C&EN Senior Editor Lisa M. Jarvis, focuses on the quiet revolution — in — that has been sweeping through biology, chemistry and other scientific fields for the last several years. It explains how scientists initially believed that cracking the , achieved a decade ago, would lay out a straight path for inventing : Identify the genetic mutation behind a disease and then find a drug that overcomes it. But scientists now know that another layer of biochemical controls, an epigenetics layer, influences how and when genes work in health and disease without changing DNA itself. Early epigenetics research already produced four drugs currently approved to treat blood cancer. But these treatments lack selectivity, limiting their effectiveness.

Now, Jarvis explains, companies like GlaxoSmithKline, Epizyme and Constellation Pharmaceuticals are moving ahead to develop the next generation of epigenetic drugs, particularly for cancer. Armed with a better understanding of how specific epigenetic enzymes are implicated in disease, they are designing compounds to block the activity of those enzymes. The article describes GSK's announcement earlier this month of an epigenetic inhibitor it has developed that might fight lymphoma. "Although no one will know the value of the new epigenetic compounds until they are tested in humans, scientists are confident that the field is moving forward with the right balance of caution and enthusiasm," Jarvis concludes.

More information: "Controlling the Code" cen.acs.org/articles/90/i16/Controlling-Code.html

add to favorites email to friend print save as pdf

Related Stories

Epigenetics and epidemiology -- hip, hype and science

Mar 15, 2012

Epigenetics is the new hip science. Time Magazine's front cover and article, 'Why your DNA isn't your Destiny' from January 2010 explains why. Its more explicit subtitle provided the hook - 'The new science of epigenetics ...

Secret funding fosters hope for new drugs for autism

Sep 15, 2010

Funding from an anonymous wealthy family has been the secret to progress, at long last, in developing drugs that show promise for helping millions of people worldwide with Fragile X syndrome, the most common genetic cause ...

Recommended for you

Changes in scores of genes contribute to autism risk

Oct 29, 2014

Small differences in as many as a thousand genes contribute to risk for autism, according to a study led by Mount Sinai researchers and the Autism Sequencing Consortium (ASC), and published today in the journal Nature.

Dozens of genes associated with autism in new research

Oct 29, 2014

Two major genetic studies of autism, led in part by UC San Francisco scientists and involving more than 50 laboratories worldwide, have newly implicated dozens of genes in the disorder. The research shows ...

Genetic link to kidney stones identified

Oct 29, 2014

A new breakthrough could help kidney stone sufferers get an exact diagnosis and specific treatment after genetic links to the condition were identified.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.